Study of Efficacy of Gabapentin in Therapy of Bronchial Asthma
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Gabapentin Efficacy in Asthma Therapy|
- At 3 months of treatment: Change from baseline of the FEV1 and PEFR (also %predicted); Number of patients without asthma symptoms
- At 3 months of treatment: FEV1 before and after salbutamol inhalation; Difference in PEF pm-am (in %); The daily (daytime and night-time) symptoms scores; % of symptom free days during the treatment period; Use of other antiasthmatic medication
|Study Start Date:||September 2003|
|Estimated Study Completion Date:||April 2004|
Effective therapy of asthma still remains quite serious problem. According GINA definition, asthma is an inflammatory disorder. Consequently, modern pharmacotherapy of asthma provides wide use of anti-inflammatory drugs. But asthma also is a paroxysmal disorder: many specialists and even some guidelines underline paroxysmal clinical picture of asthma. Besides this, according to some authors, neurogenic inflammation may play important role in asthma mechanism. But some other neurogenic inflammatory paroxysmal disorders exist, and they are migraine and trigeminal neuralgia. Some antiepileptic drugs, like carbamazepine and valproate, are very effective in therapy of migraine and trigeminal neuralgia - more than in 80% of cases. If bronchial asthma also is paroxysmal inflammatory disease, like migraine and trigeminal neuralgia, it is possible that some antiepileptic drugs also are very effective in asthma therapy.
We performed a double-blind, placebo-controlled 3-month trial for evaluation of gabapentin efficacy in therapy of bronchial asthma. Gabapentin is antiepileptic drug of new generation, produced by Pfizer.
Comparison: Patients received investigational drug in addition to their usual routine antiasthmatic treatment, compared to patients received placebo in addition to their usual routine antiasthmatic treatment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00153283
|Principal Investigator:||Merab Lomia, MD||"Rea" Rehabilitation Centre|
|Study Director:||Tamara Tchelidze, MD||CRO Evidence|
|Study Chair:||Manana Tchaia, MD||Centre of Chinese Medicine|